10-Q: Alterola Biotech Reports Increased Operating Expenses and Net Loss in Q3 2023

Alterola Biotech's Q3 2023 report reveals increased operating expenses and a larger net loss compared to the same period in 2022, alongside ongoing concerns about the company's ability to continue as a going concern.

Summary

• Alterola Biotech reported a net loss of $2,010,322 for the three months ended December 31, 2023, compared to a net loss of $534,789 for the same period in 2022.
• The company's operating expenses increased to $1,108,947 for the three months ended December 31, 2023, from $540,621 in the same period of 2022.
• For the nine months ended December 31, 2023, the net loss was $2,865,209, compared to $1,722,691 for the same period in 2022.
• Operating expenses for the nine months ended December 31, 2023, totaled $1,825,671, slightly up from $1,823,992 in the same period of 2022.
• The company has a working capital deficit of $1,160,035 as of December 31, 2023, and an accumulated deficit of $11,946,656.
• Alterola Biotech has not generated any revenue since its inception and does not anticipate revenue until it can market and sell its products.
• The company's ability to continue as a going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing.
• The company issued 587,499,996 shares in exchange for forgiveness of debt of approximately $2.35 million, resulting in a loss on exchange of $406,575.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, a going concern warning, and material weaknesses in internal controls. While the company is pursuing promising technologies, the financial risks are substantial.

Positives

• The company is actively pursuing the development of cannabinoid-based pharmaceuticals and ingredients.
• Alterola has acquired intellectual property and technology to support its product development.
• The company has a fully operational US$ and a sterling bank account in the United Kingdom with the HSBC Group.
• The company has a new CFO and Secretary, Mr. Nathan Thompson, appointed in October 2023.

Negatives

• The company has incurred significant losses since inception and has not generated any revenue.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant working capital deficit of $1,160,035.
• The company's operating expenses have increased, particularly in consulting and professional fees.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's cash position is very low, with only $2,574 in cash and cash equivalents at the end of the period.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing, which is not guaranteed.
• The company's business plan could be impaired if it is unable to secure additional funding.
• The company faces risks related to the development of its product candidates, including regulatory approvals and market acceptance.
• The company has material weaknesses in its internal control over financial reporting, which could lead to misstatements in its financial statements.
• The company's reliance on related party loans and share issuances for funding may not be sustainable.
• The company's lack of revenue generation and recurring losses pose a significant risk to its long-term viability.

Future Outlook

The company expects operational expenses to increase significantly as it progresses with research and development, regulatory compliance, and reporting obligations. The company plans to seek additional financing through private equity offerings to fund operations.

Management Comments

• Management believes in harnessing the therapeutic potential of cannabinoids and cannabinoid-like compounds.
• Management plans to continue to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures.
• Management acknowledges the substantial doubt about the company's ability to continue as a going concern.

Industry Context

The company operates in the rapidly evolving cannabinoid pharmaceutical sector, which is characterized by high research and development costs, regulatory hurdles, and significant competition. The company's focus on novel cannabinoid molecules and biosynthetic production methods aligns with industry trends towards innovation and cost reduction.

Comparison to Industry Standards

• Compared to other early-stage biotech companies, Alterola's lack of revenue and significant losses are not uncommon, but the magnitude of the accumulated deficit and the going concern warning are concerning.
• Companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) and Canopy Growth, which have developed cannabinoid-based products, have faced similar challenges in early stages, but they have also secured substantial funding and achieved regulatory approvals.
• Alterola's reliance on share issuances and related party loans for funding is not unusual for early-stage companies, but it highlights the need for more sustainable financing strategies.
• The company's focus on biosynthetic production of cannabinoids is similar to other companies exploring alternative production methods to reduce costs and improve scalability, such as Amyris and Ginkgo Bioworks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceedings.

Related Party Transactions

• A shareholder made advances to the company to fund operating expenses in the amount of $244,061.
• An officer has provided office space as an arms length transaction with rental at commercial rates.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers and suppliers may be affected by the company's uncertain future and potential inability to deliver products or services.
• Creditors face the risk of not being repaid if the company is unable to secure additional financing.

Next Steps

• The company plans to implement changes to address material weaknesses in internal control over financial reporting.
• The company intends to seek additional financing through private equity offerings.
• The company will continue to develop its product candidates and pursue regulatory approvals.

Key Dates

Keywords

cannabinoid, pharmaceutical, biotech, API, intellectual property, financial results, operating expenses, net loss, going concern, debt financing, equity financing, internal control, material weakness